Influenza, Human: all 2,265 studies
Page 16 of 23. Open to participants first (174), then studies with results posted, then the rest; newest registration first within each.
- Post-License Safety Evaluation of Influenza Virus VaccineCompletedNCT02136017
- A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and OlderCompletedNCT02133456
- Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and AboveCompletedNCT02126761Phase 1
- Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural FairsCompletedNCT02124096
- A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)CompletedNCT02121782Phase 1/2
- Effects of BCG on Influenza Induced Immune ResponseCompletedNCT02114255Phase 2/3
- Immunogenicity and Safety Study of Inactivated Split Influenza Vaccine' in Healthy Korean Male SubjectsCompletedNCT02111070Phase 1
- Treatment of Severe Influenza A InfectionCompletedNCT02108366Phase 3
- Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza VaccineCompletedNCT02107807Phase 3
- The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on DialysisStatus unknownNCT02105519Phase 4
- Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant RecipientsCompletedNCT02104869Phase 4
- Intradermal Influenza Vaccine in the YoungCompletedNCT02103023Phase 3
- Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group.CompletedNCT02101749Phase 4
- Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric PopulationsCompletedNCT02100436Phase 2
- Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical ConditionsCompletedNCT02091908Phase 3
- A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ AdjuvantCompletedNCT02078674Phase 1/2
- Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus ChallengeCompletedNCT02071329Phase 1/2
- Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ AnalyzerCompletedNCT02067286
- Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.CompletedNCT02067117Phase 4
- Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and AdultsCompletedNCT02062281Phase 4
- A Study of VIS410 to Assess Safety and PharmacokineticsCompletedNCT02045472Phase 1
- A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy SubjectsWithdrawnNCT02037282Phase 1
- Clinical Trial to Assess the Influenza Vaccination of the Hospitalized AdultsCompletedNCT02027233Not applicable
- Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316CompletedNCT02026349Phase 3
- Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.CompletedNCT02022163Phase 1
- Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human VolunteersCompletedNCT02019745
- Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United StatesCompletedNCT02019732
- Phase 1 Safety Study of Recombinant Influenza Vaccine for PreventionStatus unknownNCT02015494Phase 1
- Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy VolunteersCompletedNCT02014870Phase 1
- Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza VaccineTerminatedNCT02014168Phase 1
- Virosensor -Based Real-time Diagnosis of Enterovirus 71 and Influenza VirusStatus unknownNCT02009735Not applicable
- Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)CompletedNCT02008578Phase 1
- Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in AdultsCompletedNCT02008344Phase 3
- Screening for Silent Atrial Fibrillation During Influenza VaccinationCompletedNCT02006524Not applicable
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of AgeCompletedNCT01999842Phase 1
- A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of AgeTerminatedNCT01997450
- Randomized Controlled Trial of LAIV vs TIV Vaccines in SchoolsCompletedNCT01995851
- Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy AdultsCompletedNCT01995695Phase 1
- Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza InfectionWithdrawnNCT01992276Phase 2
- Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in AdultsCompletedNCT01991587Phase 1/2
- Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.CompletedNCT01991561Phase 2
- Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy SubjectsCompletedNCT01990846Phase 1
- Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersCompletedNCT01987011Phase 3
- The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate.Status unknownNCT01985620Not applicable
- Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older AdultsStatus unknownNCT01967368Phase 4
- A Study to Evaluate Intramuscular ASP7374CompletedNCT01961960Phase 3
- Study of ASP7374, Cell-culture-derived Influenza VaccineCompletedNCT01961947Phase 3
- Influenza Diagnosis, Treatment and Surveillance With Xpert FluCompletedNCT01947049Not applicable
- Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy RegistryCompletedNCT01945424
- Influenza Vaccine To Prevent Adverse Vascular Events:PilotCompletedNCT01945268Phase 4
- Adult Influenza Vaccination Text Message RemindersCompletedNCT01942824Not applicable
- H7N9 Mix and Match With AS03 and MF59 in Healthy AdultsCompletedNCT01942265Phase 2
- H7N9 Mix and Match With MF59 in Healthy AdultsCompletedNCT01938742Phase 2
- Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza ChallengeCompletedNCT01938352Phase 2
- Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of AgeCompletedNCT01934127Phase 1
- Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in UgandaCompletedNCT01916759Not applicable
- Japanese Pediatric H5N1 Vaccine StudyCompletedNCT01911754Phase 3
- A Post-marketing Safety Study of Beijing Tiantan Biological's Influenza Virus Vaccine in ElderlyCompletedNCT01906593
- Persistence of Immune Response After Vaccination With Influenza VaccineCompletedNCT01906190Not applicable
- A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1CompletedNCT01897701Phase 1
- Vitamin D Supplementation and the Immune ResponseTerminatedNCT01893385Phase 2
- Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)CompletedNCT01893177Phase 3
- Text Messaging Reminders for Influenza Vaccine in Primary CareCompletedNCT01892631Not applicable
- The Benefit and Harm of Fever Suppression by Antipyretics in InfluenzaCompletedNCT01891084Phase 4
- Immune Response To Intranasal Influenza VaccinationActive, not recruitingNCT01866540Not applicable
- Safety of Nasal Influenza Immunisation in Egg Allergic ChildrenCompletedNCT01859039
- Effectiveness of Influenza Vaccine Reminder SystemsCompletedNCT01852656Not applicable
- Safety of H1N1 Influenza Vaccination in Pregnant WomenCompletedNCT01842997Phase 4
- Safety and Immunogenicity of Live Attenuated Influenza H5N2CompletedNCT01841918Phase 2
- Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza PatientsCompletedNCT01839760
- Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical AfricaCompletedNCT01819155Phase 2
- A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1CompletedNCT01818362Phase 1
- Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected WomenCompletedNCT01816464Phase 4
- High-Dose Influenza Vaccine in Nursing HomesStatus unknownNCT01815268Phase 4
- Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected WomenCompletedNCT01812980Phase 4
- Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in AdultsCompletedNCT01811823Phase 4
- Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western KenyaWithdrawnNCT01810731Phase 2/3
- Combining Entertainment & Influenza Education for Pediatric PatientsCompletedNCT01788514Not applicable
- Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract InfectionsCompletedNCT01779570Phase 4
- H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and OlderCompletedNCT01774032Phase 3
- Brief Influenza Vaccine Education to Pregnant WomenCompletedNCT01772901Not applicable
- Phase-3 Study of ASP7374, Cell-culture-derived Influenza VaccineCompletedNCT01767896Phase 3
- Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014CompletedNCT01764269Not applicable
- Clinical Trial to Assess the Influenza Vaccination (FLUVAC 02)CompletedNCT01764152Not applicable
- Protecting Pregnant Women From Infectious DiseasesCompletedNCT01761799Not applicable
- Pilot Text Message for Influenza VaccinationCompletedNCT01761734Not applicable
- Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza VaccinationCompletedNCT01761435Phase 3
- Immunogenicity of Seasonal Influenza by Delivery Directly to IleumCompletedNCT01761123Phase 1
- A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly SubjectsCompletedNCT01759654Phase 3
- Safety and Immunogenicity Study of Aleph Inactivated Split Influenza VaccineCompletedNCT01758185Phase 4
- Assessment of CR8020, a Monoclonal Antibody Against Influenza A VirusesCompletedNCT01756950Phase 1
- A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years OldCompletedNCT01755364Phase 3
- Clinical Performance Study of the Ultra Influenza A&B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type BCompletedNCT01753531
- Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly SubjectsCompletedNCT01752881Phase 4
- Testing the AVI-7100 Flu Drug in Healthy VolunteersCompletedNCT01747148Phase 1
- Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly PopulationsCompletedNCT01746082Phase 2
- Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired InfluenzaCompletedNCT01740063Phase 2
- Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) AgonistsCompletedNCT01737580Phase 1
- The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza VaccineCompletedNCT01736709Phase 4
- T-705a Multicenter Study in Adults Subjects With Uncomplicated InfluenzaCompletedNCT01728753Phase 1/2